Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity upon House Dust Mite Skin Challenge in Patients Suffering from Moderate to Severe Atopic Dermatitis

Trial Profile

Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity upon House Dust Mite Skin Challenge in Patients Suffering from Moderate to Severe Atopic Dermatitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs ANB 020 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Pharmacodynamics; Proof of concept
  • Sponsors AnaptysBio
  • Most Recent Events

    • 10 Oct 2017 Top-line results presented in an AnaptysBio media release.
    • 10 Oct 2017 According to an AnaptysBio media release, Dr. Graham Ogg, professor of dermatology at University of Oxford, is the principal investigator of this trial. The company plans to report full data from this trial at a medical conference following study completion.
    • 10 Aug 2017 Status changed from recruiting to active, no longer recruiting, according to an AnaptysBio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top